<DOC>
	<DOC>NCT01683604</DOC>
	<brief_summary>This multi-center, observational study will evaluate the treatment patterns in clinical practice, efficacy and safety of tocilizumab in participants with rheumatoid arthritis (RA) who have had an inadequate response (or were intolerant to) treatment with non-biological disease-modifying anti-rheumatic drugs (DMARDs) or with one biological agent. Data will be collected from each eligible participant initiated on tocilizumab treatment by their treating physician according to approved label for 6 months from start of treatment.</brief_summary>
	<brief_title>Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Severe RA. Inadequate response (or intolerant) to nonbiological DMARDs or one biologic agent Participants initiating treatment with tocilizumab on their physician's decision (in accordance with the local label), including participants who started treatment with tocilizumab within the 8 weeks prior to the enrolment visit. Tocilizumab treatment more than 8 weeks prior to the enrolment visit. Previous tocilizumab treatment in a clinical trial or for compassionate use. Enrolled in an ongoing clinical trial and/or treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational agent, whichever is longer) before starting treatment with tocilizumab. History of autoimmune disease or any joint inflammatory disease other than RA.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>